CML to begin work on $30m API plant

By Gareth Macdonald

- Last updated on GMT

Related tags: Active ingredient

Cambridge Major Laboratories (CML) says that it will begin
construction of its new $30m (€19.2m) high tech API prodcution
facility in June.

The firm, which announced plans to invest in the new 120,000 square foot plant in February this year, said that the facility will include numerous dedicated Good Manufacturing Practice (GMP) production suites capable of making "multi-ton" quantities of several active pharmaceutical ingredients (API) at the same time. The facility, which will be located next to CML's headquarters in Germantown, Wisconsin, is expected to create between 50 and 75 additional jobs, primarily in manufacturing and production roles. CML explained that its current Germantown API facility, which was opened in 2004, is approaching its maximum operating capacity. The firm added that it needs the new plant to allow for the production of increased quantities of both developmental and commercial APIs. Company president and CEO Michael Major said that "it is vitally important for us to extend our service offerings as we have numerous projects in Phase II clinical trials and our desire is to retain the technology and customers for the initial several years of manufacturing." Ambitious corporate expansion plan ​Initially, the new Germantown site will comprise six separate manufacturing units, each with a 2,000 gallon reactor and associated isolation and containment facilities. The plant will also contain several hydrogenation and cryogenic reaction vessels, which CML said would provide considerable flexibility and allow the company to feed in work from its other API factories should the need arise. CML also said that the facility had been designed to allow for the installation of additional 4,000 gallon API manufacturing suites when the initial phase of construction is completed in August next year. ​With its November 2007 acquisition of Dutch API supplier ChemShop, subsequently renamed Cambridge Major Laboratories Europe, CML expanded its workforce to 140 employees at 3 sites in the US and Europe. Through that deal CML acquired ChemShop's 12,500 meter square API facility in Weert which features an R&D lab, several GMP kilo suites and a pilot plant production line, firmly establishing it as a major player the sector. Both the ChemShop purchase and the new Germantown production plant are part of CML's ambitious expansion program that seeks, through acquisitions and internal investment, to maintain the 30 per cent annual growth rate that the firm has enjoyed since it was founded in 1999.

Related news

Show more

Related product

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us


View more